8-K: Supernus Q2 Sales Surge, Boosts 2025 Revenue Outlook

Supernus Pharmaceuticals reported strong Q2 2025 sales for key growth products Qelbree and GOCOVRI, leading to an increased full-year revenue guidance despite a wider projected operating loss due to the Sage acquisition and higher expenses.

Summary

• Total revenues for the second quarter of 2025 were $165.5 million, a 2% decrease compared to $168.3 million in the same period of 2024.
• Total revenues excluding Trokendi XR and Oxtellar XR net sales (non-GAAP) increased by 17% to $142.7 million in Q2 2025 compared to $121.7 million in Q2 2024.
• Qelbree net sales grew 31% to $77.6 million in Q2 2025, with prescriptions increasing 23% and prescribers expanding by 23% to approximately 36,000.
• GOCOVRI net sales increased 16% to $36.7 million in Q2 2025.
• ONAPGO, launched in April 2025, generated $1.6 million in net sales in Q2 2025, with demand exceeding expectations (over 750 enrollment forms from 300+ prescribers).
• Operating income for Q2 2025 was $12.1 million, down from $22.6 million in Q2 2024, primarily due to higher contingent consideration loss and increased selling and marketing expenses.
• Net earnings for Q2 2025 were $22.5 million ($0.40 diluted EPS), up from $19.9 million ($0.36 diluted EPS) in Q2 2024.
• Cash, cash equivalents, and current marketable securities stood at approximately $522.6 million as of June 30, 2025, an increase from $453.6 million at December 31, 2024.
• The acquisition of Sage Therapeutics, Inc. was completed on July 31, 2025, adding ZURZUVAE and a CNS discovery platform.
• Full year 2025 revenue guidance was increased to $670 $700 million (from $600 $630 million), reflecting strong first-half performance and the Sage acquisition.
• Full year 2025 GAAP operating earnings guidance was updated to a loss of $(70) $(80) million (from a loss of $(15) $10 million), reflecting the Sage acquisition's impact including estimated R&D, SG&A, amortization, and one-time acquisition expenses.

Sentiment

Score: 6

Explanation: The sentiment is mixed. Strong growth in key products (Qelbree, GOCOVRI) and a significant strategic acquisition (Sage Therapeutics) are positive indicators for future revenue diversification and growth. However, the substantial decline in legacy product sales and a significantly wider projected GAAP operating loss for the full year, primarily due to acquisition-related costs and increased expenses, temper the overall positive outlook. The company is investing for future growth, which is impacting current profitability.

Positives

• Qelbree net sales increased by 31% in Q2 2025 compared to Q2 2024, reaching $77.6 million.
• GOCOVRI net sales increased by 16% in Q2 2025 compared to Q2 2024, reaching $36.7 million.
• Total IQVIA prescriptions for Qelbree increased by 23% in Q2 2025, and the prescriber base expanded by 23% to approximately 36,000.
• The launch of ONAPGO in April 2025 has seen demand exceeding expectations, with over 750 enrollment forms submitted by more than 300 prescribers by the end of Q2 2025.
• Completed the acquisition of Sage Therapeutics, Inc. on July 31, 2025, which is expected to accelerate midto long-term revenue and cash flow growth and diversify the revenue base.
• Increased full year 2025 revenue guidance to $670 $700 million, up from previous guidance of $600 $630 million.
• Net earnings and diluted earnings per share for Q2 2025 increased compared to the same period in 2024.
• Cash, cash equivalents, and current marketable securities increased to $522.6 million as of June 30, 2025, primarily due to cash generated from operations.

Negatives

• Total revenues decreased by 2% in Q2 2025 compared to Q2 2024, primarily due to significant declines in legacy products.
• Net sales of Trokendi XR decreased by 35% in Q2 2025 to $11.2 million.
• Net sales of Oxtellar XR decreased by 61% in Q2 2025 to $11.6 million.
• Operating income for Q2 2025 decreased to $12.1 million from $22.6 million in Q2 2024, driven by higher contingent consideration loss and increased selling and marketing expenses.
• Adjusted operating earnings (non-GAAP) for Q2 2025 decreased to $40.9 million from $45.5 million in Q2 2024.
• Net earnings and diluted earnings per share for the first six months of 2025 decreased compared to the same period in 2024.
• Full year 2025 GAAP operating earnings guidance was updated to a wider loss of $(70) $(80) million, compared to previous guidance of $(15) $10 million.

Risks

• Ability to sustain and increase profitability.
• Ability to raise sufficient capital to fully implement corporate strategy.
• Implementation of corporate strategy.
• Future financial performance and projected expenditures.
• Ability to increase the number of prescriptions written for products, products of subsidiaries, and products acquired through the Sage acquisition.
• Ability to increase net revenue from products, products of subsidiaries, and products acquired through the Sage acquisition.
• Ability to commercialize products, products of subsidiaries, and products acquired through the Sage acquisition.
• Ability to enter into future collaborations with pharmaceutical companies and academic institutions or to obtain funding from government agencies.
• Product research and development activities, including the timing and progress of clinical trials, and projected expenditures.
• Ability to receive, and the timing of any receipt of, regulatory approvals to develop and commercialize product candidates.
• Ability to protect intellectual property and the intellectual property of subsidiaries and operate business without infringing upon the intellectual property rights of others.
• Expectations regarding federal, state and foreign regulatory requirements.
• Therapeutic benefits, effectiveness and safety of product candidates.
• Accuracy of estimates of the size and characteristics of the markets that may be addressed by product candidates.
• Ability to increase manufacturing capabilities for products and product candidates.
• Projected markets and growth in markets.
• Product formulations and patient needs and potential funding sources.
• Staffing needs.
• Changes to laws and regulations applicable to the industry.
• Impact of macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs.

Future Outlook

The company is increasing its full year 2025 revenue guidance to $670 $700 million, primarily driven by strong first-half performance and the recent acquisition of Sage Therapeutics. However, the full year 2025 GAAP operating earnings guidance has been updated to a wider projected loss of $(70) $(80) million, reflecting the impact of the Sage acquisition, including estimated R&D, SG&A expenses, amortization of intangible assets, and one-time acquisition-related costs. Management's focus for the second half of 2025 includes the continued launch of ONAPGO, successful integration of Sage Therapeutics, and sustained performance of growth products. The pipeline continues to advance with plans to initiate a Phase 2b study for SPN-820 (depression) by the end of 2025 and disclose a lead indication for SPN-443 (ADHD/CNS) by the end of 2025.

Management Comments

• "Our strong operating performance in the first half of the year was driven by continued strong sales growth of Qelbree and GOCOVRI, which combined accounted for 72% of total net sales in the second quarter of 2025."
• "Our focus for the second half of the year remains on the launch of ONAPGO, the successful integration of Sage Therapeutics, and the continued performance of our growth products."

Industry Context

Supernus Pharmaceuticals operates in the biopharmaceutical sector, specializing in central nervous system (CNS) diseases. The acquisition of Sage Therapeutics, Inc., which adds ZURZUVAE (for postpartum depression) and a novel CNS discovery platform, signifies a strategic move to strengthen its presence in neuropsychiatric conditions. This expansion aims to accelerate midto long-term revenue and cash flow growth and diversify the company's revenue base, particularly as older products like Trokendi XR and Oxtellar XR face significant generic erosion. The focus on new product launches like ONAPGO and pipeline development in epilepsy, depression, and ADHD aligns with broader industry trends of innovation in CNS therapeutics.

Comparison to Industry Standards

• The filing does not provide specific comparable company or project results to assess performance against global benchmarks. The analysis is focused on the company's internal performance and updated guidance.

Stakeholder Impact

• Shareholders: Mixed financial results with strong growth in key products and strategic acquisition potential, but also a wider projected GAAP operating loss due to investment and acquisition costs. Long-term value proposition depends on successful integration of Sage and pipeline progression.
• Employees: Potential for integration challenges and opportunities following the Sage Therapeutics acquisition, impacting roles and organizational structure.
• Customers: Expanded product portfolio with the launch of ONAPGO and the acquisition of ZURZUVAE, offering new treatment options for CNS diseases.
• Creditors: Increased cash position provides liquidity, but the wider projected operating loss may be a point of consideration for future credit assessments.

Next Steps

• Host a conference call and webcast on August 5, 2025, to discuss financial results (already occurred on filing date).
• Archive the webcast on the company's website for 60 days following the live call.
• Initiate a follow-on Phase 2b multi-center, randomized, double-blind, placebo-controlled trial for SPN-820 (depression) by the end of 2025.
• Disclose a lead indication for the SPN-443 product candidate by the end of 2025.

Key Dates

Recommendation

While the company demonstrates strong growth in its core products (Qelbree, GOCOVRI) and has made a significant strategic acquisition (Sage Therapeutics) that promises future revenue diversification, the immediate financial outlook presents challenges. The updated full-year guidance projects a substantially wider GAAP operating loss, indicating increased expenses and integration costs associated with the acquisition. The decline in legacy product sales also remains a headwind. Given the mixed financial performance and the near-term impact of strategic investments on profitability, a 'hold' recommendation is appropriate. Investors should monitor the successful integration of Sage, the performance of new launches like ONAPGO, and the progression of the pipeline to assess the long-term value creation potential.

Keywords

Supernus, Pharmaceuticals, CNS, Qelbree, GOCOVRI, ONAPGO, Sage Therapeutics, ZURZUVAE, ADHD, Parkinson's Disease, Epilepsy, Depression, Biopharmaceutical, Earnings, Neuropsychiatric